The Problem: Safe access to FMT
Clostridium difficile is one of the most common hospital-acquired infections. About half a million Americans fall ill and nearly 30,000 people die from this aggressive intestinal bug each year.
Though C. difficile infection is often treatable with antibiotics, up to 1 in 5 patients do not respond to standard treatments.
Fecal Microbiota Transplantation (FMT) is an innovative treatment that offers great promise. Shown to be 80-91% effective across multiple randomized controlled trials, FMT involves transplanting carefully screened, processed stool from a healthy donor into a sick patient’s colon.
Despite these promising results, logistical barriers have prevented FMT from becoming widely available. It can take many hours over the course of several weeks for a patient to find a qualified stool donor, and additional time for a physician to collect, screen, and process the stool material for each individual procedure. Ultimately, the cost and coordination of performing FMT using patient-identified or physician-identified donors severely limits access for patients.
This is where OpenBiome comes in. We have become the standard of care for FMT, partnering with over 1,000 hospitals across all 50 U.S. states and Europe to expand access to FMT by providing physicians with frozen, screened, and ready-to-use fecal microbiota preparations. Our service saves physicians the time and energy of finding and processing material from healthy donors, enabling them to focus on treating patients. Our universal stool-banking model allows us to:
Produce a safe, standardized product
We rigorously screen and continuously monitor our stool donors.
We apply consistent, thorough quality and safety protocols registered with the FDA and reviewed by our clinical advisory board of 18 thought leaders in gastroenterology and infectious disease.
We save physicians the difficulty of finding and screening new donors, dramatically reducing the time required to perform an FMT from several hours to 20-30 minutes.
We supply medical centers with ready-to-use fecal microbiota preparations in advance, enabling physicians to treat patients immediately upon a medical need.
We save money by sharing the costs of screening and processing a donor’s material across many treatments.
Our universal stool banking model leverages economies of scale, enabling us to reduce costs by more than $3000 per FMT treatment.
Since our start, we have grown to partner with more than 1,000 hospitals across all 50 U.S. states.
We want to ensure that every patient suffering from recurrent C. difficile infection is able to easily and affordably access this lifesaving treatment.
Interested in working with OpenBiome? Learn more about how to partner with us here.